Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05286788 · ClinicalTrials.gov registry record · Phase 2
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
A Phase 2 study of Recurrent Adamantinomatous Craniopharyngioma and Adamantinous Craniopharyngioma, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
- 10
- Study locations
NCT05286788 is a Phase 2 study of Recurrent Adamantinomatous Craniopharyngioma and Adamantinous Craniopharyngioma that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 38 participants. The trial reports 10 study locations across 9 states.
The verdict
NCT05286788, a Phase 2 study of Recurrent Adamantinomatous Craniopharyngioma and Adamantinous Craniopharyngioma, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
- 10
- Study locations
Study Summary
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Conditions Studied
Interventions
- DRUG Binimetinib Oral Tablet [Mektovi]
Study Locations (10)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's Hospital - Columbus
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Florida
- Nicklaus Children's Hospital - Miami
New South Wales
- Sydney Children's Hospital - Randwick
Queensland
- Queensland Children's Hospital - South Brisbane
Western Australia
- Perth Children's Hospital - Perth
British Columbia
- British Columbia Children's Hospital - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2023-04-10 |
| Est. Completion | 2027-04-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05286788
The ClinicalTrials.gov registry entry for NCT05286788 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nationwide Children's Hospital, which has 188 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Recurrent Adamantinomatous Craniopharyngioma appearing as the primary indexed condition, and to 1 intervention - of which Binimetinib Oral Tablet [Mektovi] is the first listed.
NCT05286788 reports 10 study locations spanning 9 distinct geographic areas - top geographies include Ohio, Colorado, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT05286788 about?
NCT05286788 is a clinical study titled "MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma". MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug w...
What is the current status of trial NCT05286788?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2023-04-10. Estimated completion is 2027-04-10.
What conditions does trial NCT05286788 study?
This clinical trial studies the following conditions: Recurrent Adamantinomatous Craniopharyngioma, Adamantinous Craniopharyngioma.
What interventions are being tested in trial NCT05286788?
The interventions under investigation include: Binimetinib Oral Tablet [Mektovi] (DRUG).
Who is sponsoring clinical trial NCT05286788?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05286788 being conducted?
This trial has 10 study locations across Colorado, District of Columbia, Florida, Ohio, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Adamantinomatous Craniopharyngioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Recurrent Adamantinomatous Craniopharyngioma
All registered trials for this condition
Adamantinous Craniopharyngioma
All registered trials for this condition
Colorado
All trials with a study site in Colorado
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.